

Table 1: Comparison of group 1 and group 2

		Group 1	Group 2	p
Age (years)	Mean±SD	62,22±10,28	63,73±8,45	¹ 0,456
Gender	n(%)			
	Female	6 (%10,2)	4 (%10,8)	² 1,000
	Male	53 (%89,8)	33 (%89,2)	
Complaints				
	n(%)			
	Hematuria	41 (%69,5)	29 (%78,4)	³ 0,543
	Other than hematuria	9 (%15,3)	5 (%13,5)	
	Incidentally	9 (%15,3)	3 (%8,1)	
TURB pathology				
	n(%)			
	T1HG	39 (%66,1)	30 (%81,1)	³ 0,107
	T1LG	5 (%8,5)	4 (%10,8)	
	TaHG	15 (%25,4)	3 (%8,1)	
Re-TURB tumor				
	n(%)			
	No	37 (%62,7)	13 (%35,1)	³ 0,008*
	Yes	22 (%37,3)	24 (%64,9)	
Re-TURB pathology				
	n(%)			
	No	43 (%72,9)	15 (%40,5)	³ 0,001*
	Ta	10 (%16,9)	7 (%18,9)	
	T1	6 (%10,2)	15 (%40,5)	
CIS				
	n(%)			
	No	46 (%78)	25 (%67,6)	³ 0,259
	Yes	13 (%22)	12 (%32,4)	
Progression to MIBC				
	n(%)			
	No	59 (%100)	20 (%54,1)	³ 0,000*
	Yes	0 (%0)	17 (%45,9)	
Distant metastasis				
	n(%)			
	No	59 (%100)	31 (%83,8)	² 0,003*
	Yes	0 (%0)	6 (%16,2)	
Neutrophil count ($10^3/mm^3$)				
	Mean±SD	4,45±1,34	5,45±1,31	¹ 0,000*
Lymphocyte count ($10^3/mm^3$)				
	Mean±SD	2,11±0,56	2,14±0,62	¹ 0,828
Platelet count ($10^3/mm^3$)				
	Mean±SD	234,75±58,14	290,06±72,56	¹ 0,000*
NLR				
	Median (IQR)	2,04 (0,85)	2,67 (1,44)	⁴ 0,007*
PLR				
	Median (IQR)	113,2 (48,9)	142,3 (58,3)	⁴ 0,005*
SII				
	Median (IQR)	450,5 (290,6)	779,3 (284,8)	⁴ 0,000*
RFS (months)				
	Median (IQR)	27 (27)	9 (10,5)	⁴ 0,000*
PFS (months)				
	Median (IQR)	27 (27)	27 (28,5)	⁴ 0,364
Duration of follow-up (months)				
	Median (IQR)	27 (27)	39 (25,5)	⁴ 0,089

¹Student t test ²Fisher's Exact test ³Chi-square test ⁴Mann Whitney U Test *p<0.05

HG: High-grade, LG: Low-grade, CIS: Carcinoma in situ, MIBC: muscle invasive bladder cancer, NLR: Neutrophil lymphocyte ratio, PLR: Platelet lymphocyte ratio, SII: Systemic immune-inflammation index, RFS: Recurrence-free survival, PFS: Progression-free survival